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Identification of apolipoprotein n-acyltransferase (LNT) in
mycobacteria
Abstract
Lipoproteins of Gram-negative and Gram-positive bacteria carry a thioether bound diacylglyceryl but
differ by a fatty acid amide-bound to the alpha-amino group of the universally conserved cysteine. In
Escherichia coli the N-terminal acylation is catalyzed by the N-acyltransferase Lnt. Using E. coli Lnt as
a query in a BLASTp search, we identified putative lnt genes also in Gram-positive mycobacteria. The
Mycobacterium tuberculosis lipoprotein LppX, heterologously expressed in Mycobacterium smegmatis,
was N-acylated at the N-terminal cysteine, whereas LppX expressed in a M. smegmatis lnt::aph
knock-out mutant was accessible for N-terminal sequencing. Western blot analyses of a truncated and
tagged form of LppX indicated a smaller size of about 0.3 kDa in the lnt::aph mutant compared to the
parental strain. MALDI-TOF/TOF analyses of a trypsin digest of LppX proved the presence of the
diacylglyceryl modification in both strains, parental strain and lnt::aph mutant. N-acylation was found
exclusively in the M. smegmatis parental strain. Complementation of the lnt::aph mutant with M.
tuberculosis ppm1 restored N-acylation. The substrate for N-acylation is a C16 fatty acid while the two
fatty acids of the diacylglyceryl residue were identified as C16 and C19:0 fatty acid, the latter most
likely tuberculostearic acid. We demonstrate that mycobacterial lipoproteins are triacylated. For the first
time to our knowledge, we identify Lnt activity in Gram-positive bacteria and assigned the responsible
genes. In M. smegmatis and M. tuberculosis the open reading frames are annotated as MSMEG_3860
and M. tuberculosis ppm1, respectively.
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Lipoproteins of Gram-negative and Gram-
positive bacteria carry a thioether bound 
diacylglyceryl but differ by a fatty acid amide-
bound to the α-amino group of the universally 
conserved cysteine. In Escherichia coli the N-
terminal acylation is catalyzed by the N-
acyltransferase Lnt. Using E. coli Lnt as a 
query in a BLASTp search, we identified 
putative lnt genes also in Gram-positive 
mycobacteria. The Mycobacterium tuberculosis 
lipoprotein LppX, heterologously expressed in 
Mycobacterium smegmatis, was N-acylated at 
the N-terminal cysteine, whereas LppX 
expressed in a M. smegmatis lnt::aph knock-out 
mutant was accessible for N-terminal 
sequencing. Western blot analyses of a 
truncated and tagged form of LppX indicated a 
smaller size of about 0.3 kDa in the lnt::aph 
mutant compared to the parental strain. 
MALDI-TOF/TOF analyses of a trypsin digest 
of LppX proved the presence of the 
diacylglyceryl modification in both strains, 
parental strain and lnt::aph mutant. N-
acylation was found exclusively in the M. 
smegmatis parental strain. Complementation of 
the lnt::aph mutant with M. tuberculosis ppm1 
restored N-acylation. The substrate for N-
acylation is a C16 fatty acid while the two fatty 
acids of the diacylglyceryl residue were 
identified as C16 and C19:0 fatty acid, the 
latter most likely tuberculostearic acid. We 
demonstrate that mycobacterial lipoproteins 
are triacylated. For the first time to our 
knowledge, we identify Lnt activity in Gram-
positive bacteria and assigned the  responsible 
genes. In M. smegmatis and M. tuberculosis the 
open reading frames are annotated as 
MSMEG_3860 and M. tuberculosis ppm1, 
respectively. 
 
INTRODUCTION 
 
Proteins of various organisms are modified in 
numerous ways, one of them is lipidation. Lipid 
modification of proteins is common in eucaryal 
and bacterial organisms and can involve myristoyl, 
palmitoyl, isoprenyl polymers of various lengths 
or aminoglycan-linked phospholipids (1,2). 
Lipoprotein modifications investigated here are 
restricted to bacteria.  
The lipoprotein biosynthesis pathway is a major 
virulence factor in Mycobacterium tuberculosis, 
the causative agent of human tuberculosis. Every 
year 1.6 million people fall prey to tuberculosis 
and one third of the world’s population is infected 
(http://www.who.int/mediacentre/factsh 
eets/fs104/en/index.html). Thus, tuberculosis is 
responsible for 2.5 % of deaths in the world, 
which is the highest rate claimed by a single 
infectious agent. An M. tuberculosis knock-out 
mutant deficient in lipoprotein signal peptidase 
lspA showed reduced multiplication in bone-
marrow derived macrophages, complete absence 
of lung pathology and a 1000 fold reduced number 
of colony forming units in a mouse model of 
infection (3,4). Likewise, lipoprotein synthesis 
contributes to virulence of other Gram-positive 
pathogens, Listeria, Staphylococci and 
Streptococci (5). 
Bacterial lipoproteins are a functionally diverse 
class of lipidated proteins involved in cell wall 
synthesis, nutrient uptake, adhesion and 
transmembrane signalling (6) and about 2 % of 
open reading frames encode this kind of proteins 
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(7). Lipidation allows anchoring of these proteins 
to the cell surface. Lipoproteins are characterized 
by the presence of a consensus sequence, the 
“lipobox”, located in the C-terminal part of the 
leader sequence and consisting of four amino acids 
[LVI/ASTVI/GAS/C] (7). Precursor lipoproteins 
are mainly translocated in a Sec-dependent manner 
across the plasma membrane and modified 
subsequently on the universally conserved, 
essential cysteine residue located in the lipobox 
motif. The modifications taking place after 
translocation are consecutively mediated by three 
enzymes: 1. formation of a thioether linkage 
between the conserved cysteine residue and a 
diacylglycerol catalyzed by phosphatidylglycerol: 
pre-prolipoprotein diacylglyceryl transferase (Lgt), 
2. cleaveage of the N-terminal signal peptide by 
prolipoprotein signal peptidase/signal peptidase II 
(LspA) and 3. in case of Gram-negative bacteria, 
aminoacylation of the N-terminal cysteine residue 
by phospholipid:apolipoprotein N-acyltransferase 
(Lnt) (6-8). In E. coli, most of the mature 
triacylated lipoproteins are finally transported 
across the periplasm by the LolABCDE transport 
system (9). Homologues of the Lol-transport 
system are absent in Mycobacteria. Although 
lipoprotein modifying enzymes act sequentially, 
Lgt-independent LspA-mediated signal sequence 
cleveage has recently been demonstrated in 
Listeria monocytogenes (10). While Lgt and LspA 
are universally present  in both, Gram-positive and 
Gram-negative bacteria, Lnt has been reported to 
be restricted to Gram-negatives (11), although 
some indications for N-acylation in Bacillus 
subtilis and Staphylococcus aureus were reported 
(12-15).  
Mycobacterial lipoproteins are immunodominant 
antigens (16) and several manipulate innate 
immune mechanisms and antigen presenting cells 
(17). It is known that mycobacterial lipoproteins, 
e.g. the 19 kDa lipoprotein, activate toll-like 
receptor 2 (TLR2) and co–receptors TLR1, which 
recognize triacylated peptides, but also TLR6, 
which recognize diacylated peptides (18,19). 
However, the lipid linkage of mycobacterial 
lipoproteins has not been determined.  
In this study, we show that Lnt activity is more 
widely distributed than previously assumed. We 
demonstrate apolipoprotein N-acyltransferase 
activity in a Gram-positive Mycobacterium and 
give complete structural information about the 
lipid modification of mycobacterial lipoproteins. 
Hereby, the functionality of Lnt homologues in 
Actinomycetes is revealed (5). We show that 
mycobacterial lipoproteins are triacylated and 
carry mycobacteria specific fatty acids. 
 
EXPERIMENTAL PROCEDURES 
 
Bacterial strains and growth conditions 
Mycobacterium smegmatis was grown on 
Middlebrook 7H10 agar supplemented with oleic 
acid albumin dextrose (OADC, Difco) or LB agar. 
Tween 80 (0.05%) was added to liquid broth to 
avoid clumping; when appropriate, antibiotics 
were added at the following concentrations: 
kanamycin 50 µg ml−1; streptomycin 100 µg ml−1; 
hygromycin 25 µg ml−1. Strain designations were 
as follows: M. smegmatis SmR5 (20), a derivative 
of M. smegmatis mc2 (21) carrying a non-
restrictive rpsL mutation conferring streptomycin 
resistance (= parental strain); lnt::aph = lnt knock-
out mutant; lnt::aph-lntMs = M. smegmatis 
lnt::aph transformed with complementing vector 
pMV361-hyg-lntMs; lnt::aph-ppm1Tb = M. 
smegmatis lnt::aph transformed with 
complementing vector pMV361-hyg-ppm1Tb. 
 
Complementation of conditional E. coli lnt mutant 
PAP8508 
LntMs was amplified by PCR and cloned into the 
EcoRI / BamHI sites of pUC18 resulting in 
pUC18-lntMs. Plasmids pUC18-lntMs323W, 
pUC18-lntMs477Y and pUC18-lntMs323W/ 
477Y were generated by standard mutagenesis-
PCR techniques.  
The E. coli conditional lnt mutant PAP8508 and 
its parental strain PAP105 (a generous gift of N. 
Buddelmeijer) were used for complementation 
analysis (22). Strains were plated on LB agar 
supplemented with 1 mM IPTG, 100 μg / ml 
ampicillin and either 0.4 % (w/v) glucose or 0.2 % 
(w/v) arabinose. 
 
Disruption of lnt in M. smegmatis 
A 3.8 kbp genomic fragment of M. smegmatis 
from position 3’929’396 to 3’933’223 
(http://cmr.jcvi.org/cgi-bin/CMR/GenomePage.cgi
?org=gms) spanning the entire lntMs gene was 
PCR amplified and cloned into pGem-T Easy 
(Promega) to result in pGem-T Easy-lntMs. For 
functional inactivation of lntMs a 1.04 kbp SfiI / 
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EcoRV fragment was replaced with a 1.4 kbp 
SnaBI / HpaI kanamycin resistance cassette from 
pUC4K (Pharmacia) subcloned in pMCS5-Kan 
(unpublished). Subsequently a 4.6 kbp PvuII 
fragment containing the inactivated lntMs allele 
(lntMs::aph) was inserted into the EcoRV site of 
ptrpA1-rpsL (20) to result in ptrpA1-rpsL-
lntMs::aph. The lntMs::aph allele was substituted 
for lntMs in the M. smegmatis chromosome as 
described previously (23) and confirmed by 
Southern blot analyses with a 0.2 kbp SmaI / NcoI 
lntMs upstream probe.  
For complementation with M. smegmatis lnt, a 
4.3 kbp PvuII fragment from pGem-T Easy-lntMs 
comprising the entire lntMs gene was cloned into 
the HpaI site of plasmid pMV361-hyg (24) to 
result in pMV361-hyg-lntMs. For 
complementation with M. tuberculosis ppm1 a 
6.3 kbp fragment from M. tuberculosis’ genomic 
position 2’306’187 to 2’312’526 spanning the 
entire ppm1 gene was cloned into pGem-T Easy to 
result in pGem-T Easy-ppm1Tb and subsequently 
subcloned as a 6.3 kbp EcoRI fragment into the 
HpaI site of plasmid pMV361-hyg (24) to result in 
pMV361-hyg-ppm1Tb. Complementation was 
confirmed by Southern blot analyses with a 
0.2 kbp SmaI / NcoI lntMs upstream probe and a 
0.2 kbp KpnI / HindIII ppm1Tb upstream probe.  
 
Construction of expression vector pMV261-Gm-
FusLppX 
Plasmid pMV261-Gm a derivative of pMV261 is a 
shuttle vector replicating in E. coli as well as in 
mycobacteria (25). M. tuberculosis LppX was 
amplified by PCR from genomic DNA and fused 
to the M. tuberculosis 19 kDa promoter. Two 
sequences encoding a hemagglutinin and a hexa-
His epitope were fused to the 3’ part of the gene to 
facilitate subsequent purification and detection on 
Western blot and the insert was cloned into the 
EcoRI site to result in pMV261-Gm-FusLppX. 
 
Preparation of cell extracts and Western blot 
analysis 
Bacteria from 2 L cultures were harvested, 
resuspended in PBS containing Complete EDTA 
free tablets (Roche) to inhibit protein degradation 
and subjected to two French press cycles 
(American Instrument Company) at 2 × 108 Pa. 
Extracts were treated with 2 % Sodium N-
lauroylsarcosine (SLS) for 1 h at room 
temperature and subsequently incubated at 4 °C 
over night. Soluble and insoluble fractions were 
separated by centrifugation at 30’000 g for 1 h at 
4 °C. Extracts corresponding to 1–5 µg of total 
protein were separated by SDS-PAGE (12%) and 
analyzed by Western blot. Antiserum against HA 
epitope (Roche) was diluted 1:300. 
 
FPLC protein purification 
The soluble fraction of cell extracts was diluted 
with buffer containing 20 mM NaH2PO4, 0.5 M 
NaCl to 1 % SLS and loaded on HisTrap™ HP 
column (GE Healthcare) equilibrated with buffer 
containing 20 mM NaH2PO4, 0.5 M NaCl, 0.2 % 
SLS and 20 mM imidazole. Proteins were eluted 
with 0.125-0.5 M imidazole.  
 
Thrombin cleavage of RecLppX 
Purified RecLppX was dialyzed against PBS pH 
7.4 at 4 °C because imidazole can lower thrombin 
activity (26). About 0.1-1 μg RecLppX was 
digested with 4-30 NIH units of thrombin from 
bovine plasma (Sigma) for 16 h at 37 °C with 
continuous shaking (25 rpm). Reaction was 
stopped through incubation at 95 °C for 5 min. 
 
MALDI-TOF/TOF 
Purified lipoprotein (100-200 pmol) were prepared 
and analysed according to Ujihara et al. (27). After 
tryptic digestion samples were resuspended in 5 μl 
0.1 % trifluoroacetic acid, 66 % acetonitrile. 1.2 μl 
were loaded onto the target and covered with 1 μl 
matrix (α-cyano-4-hydroxy-cinnamic acid (Bruker 
Daltonics), 5 mg/ml in 0.1 % TFA, 50 % 
acetonitrile). Mass spectra were recorded on an 
Ultraflex II MALDI-TOF/TOF instrument with 
smartbeam laser upgrade (Bruker, Germany). The 
frequency-tripled Nd:YAG laser using a 
structured-focus profile (smartbeam, Bruker-
Daltonics) was set to a repetition rate of 100 Hz 
and the ion acceleration voltage was 29.5 kV. The 
mass measurements were performed in the 
positive ion reflector mode. 
 
RESULTS 
 
Mycobacterial lipoproteins are modified at the 
N-terminus 
We chose the well characterized M. tuberculosis 
lipoprotein LppX (28) as a model substrate for 
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mycobacterial lipoprotein synthesis and generated 
the expression vector pMV261-Gm-FusLppX. 
Plasmid pMV261-Gm-FusLppX was transformed 
into M. smegmatis SmR5 (20), M. smegmatis 
ΔlspA and complemented M. smegmatis ΔlspA-
lspA (unpublished). Whole cell extracts of these 
strains were subjected to Western blot analysis 
with anti-HA antibody. We observed bands with 
an apparent size of 23 kDa in parental and 
complemented strain and 26 kDa in the ΔlspA 
mutant and to a little amount also in the parental 
strain. After purification of LppX, the 26 kDa 
band was also detected to a higher amount in the 
parental strain. The 23 kDa band corresponds to 
the predicted mass of mature recombinant LppX-
HA-His and 26 kDa band to the predicted mass of 
the prolipoprotein form of LppX-HA-His. These 
results indicate LspA-dependent signal peptide 
cleavage of recombinant LppX-HA-His in M. 
smegmatis and verify its post-translational 
modification within the lipoprotein synthesis 
pathway (Figure 1a). 
Purified LppX-HA-His from M. smegmatis 
parental strain was subjected to protein sequence 
analysis. Edman degradation of the prolipoprotein 
revealed a sequence starting at the initial 
methionine of the signal peptide of LppX (Figure 
1b). In contrast, no sequence was obtained from 
the mature LppX indicating a modification of the 
N-terminal amino group. 
 
Identification of putative N-acyltransferases in 
bacterial genomes 
In E. coli, N-acylation of lipoproteins is conferred 
by Lnt (29). We performed a BLAST 
search analysis (http://www.ncbi.nlm.nih.gov/sutil
s/genom_table.cgi) with E. coli Lnt as a query to 
investigate the distribution of Lnt homologues in 
the bacterial kingdom and to identify putative 
homologues in mycobacteria. Lnt homologues are 
widely distributed in Gram-negative bacteria 
(α,β,γ,δ,ε Proteobacteria, Spirochetes, Aquifex, 
Cytophaga, Thermotoga), but absent from all 
classes (Clostridia, Mollicutes, Bacilli) of low GC 
Gram-positive bacteria (Firmicutes), although 
some indications for N-acylation in low GC Gram 
positives have been reported (12-15). In contrast, 
Lnt homologues were identified in all classes of 
high GC Gram-positive bacteria (Actinobacteria, 
e.g. Streptomyces, Nocardia, Corynebacteria and 
Mycobacteria) (Figure 2a), but Lnt activity of 
those homologues could not be demonstrated (22). 
The cell envelope of the phylum Actinobacteria is 
more complex than the cell envelope of 
Firmicutes. In M. tuberculosis and M. smegmatis, 
Rv2051c (Ppm1) and MSMEG_3860 (Ppm2) have 
the highest similarity to E. coli Lnt. 
M. tuberculosis Rv2051c encodes a two-domain 
protein, of which the N-terminal part shows 
similarity to E. coli Lnt. The C-terminal part of the 
protein encodes a polyprenol-
monophosphomannose (Ppm) synthase, an 
enzyme involved in lipomannan and 
lipoarabinomannan synthesis (30). MSMEG_3860 
has been shown to stabilize M. smegmatis Ppm1 in 
the bacterial membrane and therefore has been 
annotated as Ppm2 (31). MSMEG_3860 will be 
referred to as LntMs here. Lnt homologues are 
also present in Mycobacterium avium and 
Mycobacterium leprae and are encoded by a 
separate open reading frame as in M. smegmatis. 
The genomic region surrounding Lnt homologues 
is conserved in mycobacteria (Figure 2b). 
 
M. smegmatis Lnt does not restore growth of a 
conditional E. coli lnt mutant 
All enzymes of the lipoprotein synthesis pathway 
are essential in Gram-negatives. We intended to 
demonstrate mycobacterial Lnt activity by 
complementation of an E. coli conditional lnt 
mutant. Since LntMs is encoded by a separate 
open reading frame and is not fused to a second 
domain as in M. tuberculosis, we chose M. 
smegmatis Lnt (MSMEG_3860) instead of M. 
tuberculosis Ppm1 (Rv2051c) for 
complementation. LntMs encodes a protein of 654 
amino acids with a 25 % identity and 40 % 
similarity to E. coli and a 63 % identity and 73 % 
similarity to the N-terminal part of M. tuberculosis 
Rv2051c. LntMs was cloned into vector pUC18 
(Fermentas) to result in pUC18-lntMs and 
transformed into the conditional E. coli lnt mutant 
PAP8508 (22). However, we could not restore 
growth of the PAP8508 mutant under restrictive 
conditions (data not shown). Seven amino acids 
(W237, E267, K335, E343, C387, Y388, E389) 
are reported to be essential for E. coli Lnt function 
(22). Five of these seven residues are conserved in 
LntMs, while two are altered (LntEc W237 
corresponds to LntMs E323, LntEc Y388 
corresponds to LntMs W477). We exploited site 
directed mutagenesis to introduce these E. coli 
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codons into the M. smegmatis sequence of pUC18-
lntMs to result in pUC18-lntMs323W, pUC18-
lntMs477Y and pUC18-lntMs323W/477Y. 
However transformation of none of these vectors 
complemented the conditional E. coli lnt mutant 
(data not shown). 
 
Generation and characterization of 
M. smegmatis lnt::aph mutant 
Since we were unable to complement an E. coli lnt 
mutant, we decided to investigate Lnt activity 
directly in mycobacteria by generating a 
M. smegmatis lnt deletion mutant. The deletion 
mutant was constructed by transformation of M. 
smegmatis SmR5 with the suicide plasmid ptrpA1-
rpsL-lntMs::aph using the rpsL counterselection 
strategy (20). The mutant strain resulting from 
allelic replacement is here referred to as M. 
smegmatis lnt::aph. Deletion of lntMs was verified 
by Southern blot analysis using a 5’ lntMs DNA 
probe (Figure S1). The probe hybridized to a 1.4 
kbp fragment of the parental strain and a 6.4 kbp 
fragment of the lnt::aph mutant. The difference in 
size results from the deletion of a BstEII restriction 
site and insertion of a kanamycin resistance 
cassette. We cloned two complementation vectors 
(pMV361-hyg-lntMs and pMV361-hyg-ppm1Tb) 
expressing M. smegmatis Lnt and M. tuberculosis 
Ppm1 under control of their native promoters. 
Transformation of these plasmids into 
M. smegmatis lnt::aph mutant resulted in strains 
M. smegmatis lnt::aph-lntMs and M. smegmatis 
lnt::aph-ppm1Tb. 
Western blot analysis of extracts from 
M. smegmatis lnt::aph expressing LppX-HA-His 
revealed a molecular mass of the detected protein, 
which can not be distinguished from that of LppX-
HA-His expressed in M. smegmatis parental strain. 
However, N-terminal sequencing revealed that 
LppX-HA-His purified from M. smegmatis 
lnt::aph is accessible to Edman degradation 
(sequence CSSP) indicating that the N-terminal 
amino group is not blocked anymore. 
 
LntMs and Ppm1Tb are apolipoprotein N-
acyltransferases 
Since fatty acids of membrane phospholipids are 
the substrates for N-acylation of lipoproteins in 
E. coli (32-34), its lipoproteins are modified with 
myristic, palmitic, palmitoleic, oleic or vaccinic 
acid (35). Phospholipids in mycobacteria mainly 
consist of palmitic, palmitoleic, oleic and 
tuberculostearic acid (10-methyloctadecanoic 
acid) (36). Therefore we hypothesized that N-
acylation of lipoproteins in mycobacteria increases 
the molecular mass by approximately 0.3 kDa. To 
differentiate between lipoproteins with a free or 
acylated N-terminus, we cloned an additional 
expression vector, RecLppX. It differs from 
LppX-HA-His by a hemagglutinin epitope 
followed by a thrombin cleavage site inserted after 
amino acid Ala (+19) of the mature LppX (Figure 
1b). The thrombin cleavage site LVPRGS was 
inserted to produce a small N-terminal fragment of 
33 residues (about 3.5 kDa) after thrombin 
cleavage. To ensure that the insertion of a HA-
epitope and a thrombin site does not abolish 
recognition of RecLppX as a lipoprotein, we 
analyzed total lysates of M. smegmatis parental 
strain, M. smegmatis ΔlspA and M. smegmatis 
ΔlspA-lspA by Western blot (Figure 3a). 
Temperature-sensitive lspA mutants of E. coli and 
lspA knock-out mutants of Gram-positive bacteria 
accumulate prolipoproteins (37,38). 
Immunoblotting of total lysates of M. smegmatis 
parental strain, ΔlspA and ΔlspA-lspA with 
antiserum against the HA-epitope (Roche) 
revealed the presence of a 25 kDa band in parental 
and complemented strains. In contrast, a band with 
a slightly larger size (appr. 27 kDa, the increase 
corresponds to the mass of the signal sequence) 
was observed in the ΔlspA strain. This result 
shows that the insertion of a HA-epitope and a 
thrombin cleavage site did not impair the 
recognition of RecLppX as a lipoprotein. We then 
investigated thrombin digested RecLppX for Lnt-
dependent modification by Western blot analyses 
(Figure 3b). In the lnt::aph mutant we observed a 
slightly smaller size of the N-terminal part of 
RecLppX suggesting, that there are fewer 
modifications on the protein compared to parental 
strain and both complemented strains lnt::aph-
lntMs and lnt::aph-ppm1Tb. In all strains, we also 
found a double band of the N-terminal part of 
RecLppX, indicating partial modification of 
RecLppX by other enzymes than Lnt or LspA. We 
also observed a deviation from the calculated size 
of the N-terminal part of mature RecLppX. The 
molecular mass was calculated to be 3.5 kDa but 
in the parental strain we found a band 
corresponding to a size of about 6 kDa. This 
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difference in size is probably due to an altered 
migration behaviour because of lipid 
modifications. It can be excluded that these bands 
at 6 kDa are prolipoprotein forms, still containing 
the signal peptide, because the N-terminal part of 
pro-RecLppX from ΔlspA mutant is running at 
about 8.5 kDa. These results show that RecLppX 
is modified by LspA as well as by LntMs. 
Ppm1Tb is sufficient to replace LntMs implicating 
that similar lipoprotein modifications take place in 
M. tuberculosis.  
Recombinant M. tuberculosis LppX (FusLppX) 
was heterologously expressed and purified. 
Tryptic fragments of FusLppX were analyzed by 
MALDI-TOF/TOF mass spectrometry to 
characterize modifications taking place on 
lipoproteins in M. smegmatis at the molecular 
level. Purified mature LppX from parental strain, 
lnt::aph mutant and lnt::aph-ppm1Tb was 
prepared for analysis according to Ujihara et al. 
(27). For identification of the modifications of the 
universally conserved cysteine, the structure of the 
N-terminal tryptic peptide was determined. 
Experimentally found m/z values are summarized 
and compared to calculated m/z values in Table 1. 
Trypsin cleavage sites of LppX are given in Figure 
1b. The expected monoisotopic molecular mass of 
the unmodified N-terminal tryptic peptide of LppX 
is 2963.46 Da. Instead, we found a [M+H]+ signal 
at m/z = 3795.42 for the N-terminal tryptic peptide 
of LppX from parental strain and a signal at m/z = 
3557.01 from the lnt::aph mutant. The N-terminal 
tryptic peptide from lnt::aph-ppm1Tb is a mixture 
and showed signals of m/z = 3795.32 and 3557.07 
(Figure 4). This indicates that the N-terminal 
peptide of LppX is modified in an LntMs 
dependent manner. To identify the found 
modification, we calculated diacylglyceryl 
modifications with all theoretical combinations of 
the four fatty acids found in mycobacterial 
phospholipids: palmitic acid (C16:0), palmitoleic 
acid (C16:1), oleic acid (C18:1) and 
tuberculostearic acid (C19:0). The difference in 
molecular mass between the peptide of the 
lnt::aph mutant and the unmodified peptide is 
592.55 Da indicating a diacylglyceryl modification 
with ester-linked C19:0 and C16:0 fatty acid. 
These fatty acids are most likely tuberculostearic 
acid and palmitic acid. 
The difference in molecular mass of 238.41 Da 
between lnt::aph mutant (m/z = 3557.07) and 
parental strain (m/z = 3795.42) indicates an 
additional modification with a C16:0 fatty acid in 
the parental strain. By thorough analyzing the 
signal at m/z = 3795.42 in high resolution, we also 
observed a minor signal (approx. 10 %) at m/z = 
3793.35. This indicates the presence of a C16:1 
fatty acid in place of the C16:0 fatty acid, but only 
to a little amount (data not shown). In the 
complemented mutant lnt::aph-ppm1Tb both 
forms of the N-terminal tryptic peptide of LppX 
were found. This finding indicates partial 
complementation of LntMs by M. tuberculosis 
Ppm1. 
In the lnt::aph and the lnt::aph-ppm1Tb mutant 
we additionally found an N-terminal tryptic 
peptide at a signal of m/z = of 3739.18 and 
3739.32, respectively. But no evidence for an 
amino-acyl modification was found in the MS/MS 
fragmentation pattern. In contrast, the release of 
183 Da most likely corresponds to a covalent 
modification of the free N-terminal amino group 
of LppX in these two strains with 4-(2-
Aminoethyl)-benzenesulfonyl fluoride (AEBSF), a 
component of the protease inhibitor mix which has 
been used. AEBSF is known to modify 
hydroxylated amino acids and to a lesser extent 
also free amino groups (http://www.abrf.org/ 
index.cfm/dm.details?DMID=235&AvgMass=183
&Margin=0). 
To obtain information about linkage of the 
modifications, the structure of the triacylated N-
terminal tryptic peptide of LppX (m/z = 3795.42) 
was investigated by MS/MS (Figure 5, Figure S2). 
A summary of all found eliminations in the three 
strains are given in Table 2. The ions at m/z = 
3539.59 and at m/z = 3496.52 correspond to the 
neutral loss of a C16 (Δ = 255.82 Da) and a C19:0 
fatty acid (Δ = 298.89 Da), respectively. The most 
intense fragment ion at m/z = 3169.21 corresponds 
to the elimination of a diacylthioglyceryl carrying 
both O-linked C19:0 and C16 fatty acids (Δ = 
626.22 Da). In addition the release of 370.38 Da 
from the ion at m/z = 3539.59 corresponds to the 
elimination of a C19:0 fatty acid α-thioglyceryl 
ester and the release of 327.31 Da from the ion at 
m/z = 3496.52 corresponds to the elimination of a 
C16 fatty acid α-thioglyceryl ester. This 
fragmentation pattern shows, that the +1 cysteine 
is modified at the sulfhydryl group by a 
diacylglyceryl-residue carrying ester bound C16 
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fatty acid and C19:0 fatty acid. Whether the C19:0 
fatty acid is in the SN1 or SN2 position can not be 
determined. The release of 255.08 Da from the ion 
at m/z = 3169.21 indicates the release of a 
palmitamide derived from an amide-bound C16 
fatty acid. The MS/MS fragmentation pattern of 
LppX N-terminal tryptic peptide of the lnt::aph 
mutant (m/z = 3557.07) showed only the 
elimination of the diacylthioglycerol, but no 
release of palmitamide, as expected (Figure 5). 
In order to verify the diacylglyceryl modification, 
we also analysed tryptic peptides of LppX from 
the ΔlspA mutant by MALDI-TOF/TOF mass 
spectrometry (Figure 6). Experimentally found 
m/z values are summarized and compared to 
calculated m/z values in Table 3. Trypsin cleavage 
sites of pro-LppX are given in Figure 1b. We 
found three m/z signals corresponding to the 
tryptic peptide containing the +1 cysteine. The 
signal at m/z = 4887.30 corresponds to the peptide 
with a disulfide bridge between the two present 
cysteines (position -8 and +1). The signal at m/z = 
5041.23 corresponds to the peptide with both 
cysteines being modified by β-mercaptoethanyl, a 
buffer component used for SDS-PAGE. The signal 
at m/z = 5558.12 corresponds to the peptide with 
one cysteine being modified with a β-
mercaptoethanyl but the other being modified with 
the diacylglyceryl carrying O-linked C16 and 
C19:0 fatty acids also found in the previously 
analysed strains (Figure 6). This result shows that 
LppX purified from the ΔlspA mutant is a mixture 
of pre-pro-LppX and pro-LppX. 
Taken together the results show that the 
universally conserved cysteine of M. tuberculosis 
LppX is modified with a thioether linked 
diacylglyceryl residue carrying an ester-bound 
C19:0 and an ester-bound C16 fatty acid. In 
addition, it is modified with an amide-linked third 
C16 fatty acid. The C19:0 fatty acid corresponds 
most likely to the mycobacterial specific 
tuberculostearic acid. It is also proved, that LntMs 
is an N-acyltransferase and M. tuberculosis Ppm1 
is able to complement M. smegmatis lnt::aph 
mutant and therefore Ppm1 seems to be a 
bifunctional protein. Within this protein the N-
terminal domain presumably exhibits N-
acyltransferase activity (our data) and the C-
terminal domain exhibits mannosyl transferase 
activity (30). 
DISCUSSION 
 
The lipoprotein biosynthesis pathway consisting of 
the three enzymes Lgt, LspA and Lnt has been 
intensively studied in E. coli and has been shown 
to be essential and necessary for transport of 
lipoproteins to the outer membrane of Gram-
negative bacteria (11,39,40). In mycobacteria, 
little is known about synthesis and localization of 
lipoproteins, only a few lipoproteins are 
functionally characterized and annotation is 
mainly based on theoretical considerations instead 
of experimental evidence. However, consistent 
with the biosynthetic pathway in E. coli, putative 
lgt (Rv1614) and lsp (Rv1539) genes have been 
identified in the M. tuberculosis genome (41). In 
revious studies we could show that in 
mycobacteria the lipoprotein pathway is a major 
virulence factor (3,4). For fundamental knowledge 
and further investigations, we were interested in 
how lipoproteins are modified in mycobacteria. In 
the present study, we investigated the lipid 
moieties of a representative mycobacterial 
lipoprotein. 
We identified Lnt homologues in mycobacteria, 
corynebacteria and streptomyces species. In low 
GC Gram positive bacteria Lnt homologues are 
completely absent (Figure 2), but in 1985 the first 
indirect detection of N-acylation in the Gram-
positive Bacillus subtilis was published and in S. 
aureus triacylation of lipoprotein SitC was 
recently reported (14,15), while another 
lipoprotein (SAOUHSC_02699) was only found to 
be diacylated (13). The protein responsible for 
attaching the third fatty acid to lipoproteins in S. 
aureus has not been identified. It may be 
differentially expressed depending on culture 
conditions or may have a narrow substrate 
specificity. In M. tuberculosis the Lnt homologue 
found, is annotated as Rv2051c. This ORF was 
originally annotated as a two-domain enzyme with 
a putative N-terminal Lnt domain and a C-terminal 
polyprenol monophosphomannose synthase 
(Ppm1) domain and was characterized as the latter 
one (30). Although the putative Lnt domain is not 
needed for Ppm1 activity, on overexpression in M. 
smegmatis it appeared to enhance the 
mannosyltransferase activity. Interestingly, the 
two domains of M. tuberculosis Ppm1 are encoded 
by separate, adjacent open reading frames in the 
genomes of other mycobacteria (Figure 2b). 
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Previous attempts to complement a conditional 
E. coli lnt mutant with Lnt homologues from other 
bacterial species corresponding to the order 
Actinomycetales (Streptomyces, 
Corynebacterium) failed (22). Likewise we were 
unable to complement this E. coli strain with a 
mycobacterial Lnt homologue. Even after 
exchange of the two essential amino acids 
differing between M. smegmatis and E. coli, 
complementation of E. coli lnt mutant failed. 
LntMs as E. coli Lnt attaches a C16 fatty acid to 
the free amino group of the universally conserved 
cysteine. Therefore the failure of complementation 
is not due to absence of fatty acid substrates. 
Rather mycobacterial lipoproteins are modified 
with a diacylglyceryl carrying mycobacterial 
specific fatty acids. Failure of complementation of 
PAP8508 therefore is probably due to the fact that 
LntMs recognizes only lipoproteins modified with 
a diacylglyceryl residue carrying at least one ester 
bound mycobacterial specific fatty acid. This 
implies that LntMs does not recognize lipoproteins 
modified with diacylglyceryl residues carrying 
only small fatty acids like palmitic or palmitoleic 
acid. Specificity could be tested in an in vitro 
assay system. Alternatively, the expression level 
or enzymatic activity of mycobacterial Lnt 
homologues may not sustain growth of fast 
growing E. coli.  
We then investigated LntMs and M. tuberculosis 
Ppm1 activity in a mycobacterial background. As 
lntMs is not an essential gene in mycobacteria, we 
generated an isogenic M. smegmatis lnt::aph 
mutant. After thrombin cleavage, the recombinant 
lipoprotein (RecLppX) extracted from 
M. smegmatis lnt::aph mutant showed a faster 
running behaviour on SDS-PAGE than RecLppX 
extracted from the parental strain. The size was 
about 0.3 kDa smaller corresponding to fewer 
modifications of RecLppX in the lnt::aph mutant. 
We also recognized a double band of digested 
RecLppX in all strains used as well as a 
discrepancy between the calculated and the 
apparent molecular mass. The altered running 
behaviour is probably due to the modifications on 
the small N-terminal fragment and the observed 
double band indicates partial processing of 
RecLppX by enzymes other than Lgt, LspA or 
Lnt. Glycosylation of RecLppX is one possibility, 
but information about the structure, function, and 
biosynthetic pathways of prokaryotic 
glycoproteins is scarce. Glycosylation of M. 
tuberculosis lipoproteins has been confirmed for 
the 45/47 kDa protein, SodC and for the 
Mycobacterium bovis MPB83 protein (Rv2873) 
(42-44). Glycosylation of SodC influences its 
ultimate subcellular localization and also its 
proteolytic processing.  
By performing MALDI-TOF/TOF analyses of a 
trypsin digest of purified LppX we unambiguously 
identified modifications at the universally 
conserved cysteine. After trypsin cleavage of 
LppX, the N-terminal peptide from the parental 
strain has a mass of 3794.41 Da instead of 2963.46 
Da predicted for the unmodified peptide, whereas 
the N-terminal peptide from the isogenic lnt::aph 
mutant showed a mass of 3556.01 Da. This 
strongly indicates that LntMs covalently links a 
C16 fatty acid (C16:0 or C16:1) to the N-terminus 
of the peptide. The additional increase by 592 Da 
corresponds to a diacylglyceryl residue with C16 
fatty acid and a C19:0 fatty acid, which 
corresponds most likely to tuberculostearic acid 
(10-methyloctadecanoic acid), forming a 
thioether-linkage to the sulfhydryl group of the 
cysteine. Whether the C19:0 fatty acid is in the 
SN1 or SN2 position can not be determined. The 
same diacylglyceryl modification was also found 
in the ΔlspA mutant. The loss of the N-acyl 
modification in the lnt::aph mutant is 
complemented by the M. tuberculosis homologue 
Ppm1 suggesting that mature M. tuberculosis 
lipoproteins are N-acylated. N-acylation affects the 
interaction of lipoproteins with innate immune 
receptors (45). Ppm1 was shown to exhibit 
polyprenol-monophosphomannose synthetase 
activity (30) although the major part of the protein 
has homology to E. coli Lnt. Both masses of the 
N-terminal tryptic peptide (3556.07 Da and 
3794.32 Da) were found in the complemented 
mutant indicating that not all apolipoprotein was 
converted to mature lipoprotein by Ppm1. As M. 
tuberculosis has a generation time of about 24 
hours and M. smegmatis only of about 3 hours, it 
is possible that M. tuberculosis Ppm1 has a lower 
enzymatic activity than LntMs. Alternatively, the 
expression level of M. tuberculosis Ppm1 is lower 
than that of M. smegmatis Lnt. 
The identification of O-linked tuberculostearic 
acid shows that mycobacterial lipoproteins are 
modified with mycobacterial specific fatty acids 
and differ from lipoproteins modified in E. coli. 
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In this study we directly show, that Gram-positive 
mycobacteria synthesize triacylated lipoproteins. 
This is the first time to our knowledge that 
responsible genes for Lnt activity are assigned in 
Gram-positive bacteria. LntMs and 
M. tuberculosis Ppm1 are functional homologues 
of E. coli Lnt as they catalyze the transfer of the 
third acyl moiety to the free α-amino group of the 
N-terminal amino acid of lipoproteins. Most likely 
mycobacterial Lnt homologues differ in substrate 
specificity from E. coli Lnt. N-acylation is a 
prerequisite for transport of E. coli lipoproteins to 
the outer membrane (46). Likewise, N-acylation of 
mycobacterial lipoproteins may be required for 
transport to the outer most lipid layer of 
mycobacteria which according to recent 
investigations resembles the outer membrane of 
Gram-negatives (47,48). 
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FIGURE LEGENDS 
 
Figure 1: Western blot analysis of LppX 
a) total lysates of M. smegmatis parental strain, ΔlspA, ΔlspA-lspA expressing LppX with hemagglutinin 
(HA) and hexa-His epitope analysed with mouse anti-hemagglutinin monoclonal antibody; b) amino acid 
sequence of LppX-HA-His. Inverted commas show trypsin cleavage sites. The arrow shows the +1 
cysteine modified by Lgt and Lnt. Bold letters indicate the signal sequence cleaved off by LspA reducing 
the molecular weight by 2.6 kDa. Italic letters indicate the modified tryptic peptide in the ΔlspA mutant, 
underlined is the N-terminal tryptic peptide found in M. smegmatis parental strain, lnt::aph mutant and 
lnt::aph-ppm1Tb. 
 
Figure 2: Lnt-BLASTp.  
a) E. coli Lnt was used as a query to identify homologues on the National Center for Biotechnology 
Information BLASTp server (http://www.ncbi.nlm.gov/sutils/genom_table.cgi). The sequence filtering 
option was switched off and the expect value was set at 10, the cut-off value set at 10-4. b) a comparison 
of the genomic region of Lnt (black) and Ppm1 (grey) homologues in mycobacteria.  
 
Figure 3: Western blot analysis of RecLppX 
a) total lysates of M. smegmatis wildtype, ΔlspA, ΔlspA-lspA expressing RecLppX with hemagglutinin 
and hexa-His epitope analyzed with mouse anti-hemagglutinin monoclonal antibody. b) RecLppX 
isolated from indicated strains was digested with thrombin and analyzed with mouse anti-hemagglutinin 
monoclonal antibody. 
 
Figure 4: MALDI-TOF analysis of a trypsin digest of purified LppX 
MS analysis of LppX tryptic peptides purified from M. smegmatis parental strain (1); M. smegmatis 
lnt::aph (2) and M. smegmatis lnt::aph-ppm1Tb (3). Filled triangle = diacylglyceryl plus N-acyl modified 
N-terminal peptide; open triangle = diacylglyceryl modified N-terminal peptide. 
 
Figure 5: MALDI-TOF-TOF analysis of the N-terminal peptides of LppX 
MS/MS analysis of N-terminal peptides of LppX purified from M. smegmatis parental strain (1), 
M. smegmatis lnt::aph (2) and M. smegmatis lnt::aph-ppm1Tb (3). A schematic drawing of the modified 
+1 cysteine with the cleavage sites of each identified m/z signal is depicted in the upper part of each 
spectrum. The eliminated fragments of LppX modifications are shown on the right side of spectrum (1): 
c palmitic acid; d tuberculostearic acid; e diacylthioglycerol; f tuberculostearic acid α-thioglyceryl 
ester; g palmitic acid α-thioglyceryl ester; h palmitamide. Note that the ester-linked palmitic acid and 
tuberculostearic acid may be coupled to either position SN1 or SN2. Only one conformation is depicted. 
 
Figure 6: MALDI-TOF analysis of peptides resulting from trypsin digestion of LppX from ΔlspA 
mutant 
MS analysis of LppX tryptic peptides purified from M. smegmatis ΔlspA mutant. Arrows indicate the N-
terminal peptides. Asterisk = N-terminal peptide without fatty acid modifications; open triangle = 
diacylglyceryl modified N-terminal peptide. 
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Table 1: Comparison of m/z values of LppX N-terminal tryptic peptides found in the different 
mutants  
CSS…EIR corresponds to the N-terminal tryptic peptide of LppX upon cleavage of the signal peptide by 
LspA (Figure 1b). Mass differences to the corresponding unmodified peptide (upper row) due to 
modifications are given in brackets. Observed modifications are: diacylglyceryl with a C16 fatty acid and 
tuberculostearic acid (C19:0) (+ 592.54 Da), plus eventually N-acyl with C16 fatty acid (+ 238.23 Da, 
Σ = 830.77 Da). 
 
peptide calculated m/z parental strain m/z lnt::aph m/z 
lnt::aph-ppm1Tb 
m/z 
CSS...EIR 2964.46 - - - 
CSS...EIR 
+ diacylglyceryl 
(C19,C16) 
3557.01 
(+ 592.54) - 
3557.01 
(+ 592.55) 
3557.07 
(+ 592.61) 
CSS...EIR 
+ diacylglyceryl 
(C19,C16) 
+ N-acyl (C16) 
3795.24 
(+ 830.77) 
3795.42 
(+ 830.95) - 
3795.32 
(+ 830.86) 
 
 
 
 
 
Table 2: Comparison of experimentally determined eliminations from N-terminal tryptic peptides 
of LppX in the MALDI-TOF/TOF spectra of the different mutants with theoretically calculated 
eliminations 
 
  experimentally determined mass of eliminated fragment in 
modification eliminated fragment 
calculated 
mass of 
eliminated 
fragment 
[Da]* 
parental 
strain [Da] 
lnt::aph 
[Da] 
lnt::aph -
ppm1Tb 
[Da] 
O-linked palmitoyl palmitic acid 256.24 255.84 256.36 255.68 
N-linked palmitoyl palmitamide 255.26 255.08 - 255.80 
O-linked 
tuberculostearyl tuberculostearic acid 298.29 298.92 - - 
diacylglyceryl 
(C16,C19) 
diacylthioglyceryl 
(C16,C19) 626.53 626.22 626.78 626.16 
 C16 fatty acid α-thioglyceryl ester 328.24 327.30 - - 
 tuberculostearic α-thioglyceryl ester 370.29 370.38 370.43 370.48 
*: calculated masses are monoisotopic masses 
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Table 3: Comparison of m/z values of tryptic peptides of pro-LppX containing the +1 cysteine 
found in the ΔlspA mutant 
AVT…EIR corresponds to the tryptic peptide of pro-LppX containing the +1 cysteine (Figure 1b). Mass 
differences to the corresponding unmodified peptide due to modifications are given in brackets. Observed 
modifications are: diacylglyceryl with C16 and C19 fatty acid (+ 592.54 Da), β-mercaptoethanyl (+ 76.00 
Da). 
 
peptide calculated m/z ΔlspA m/z 
AVT...EIR with unmodified 
cysteines 4888.55 - 
AVT...EIR with S-S 4886.53 4887.30 
AVT...EIR  
+ 2x mercaptoethanyl 
5040.54 
(+ 152.00) 
5041.23 
(+ 152.68) 
AVT...EIR 
+ 1x mercaptoethanyl 
+ diacylglyceryl (C19,C16) 
5557.09 
(+ 668.54) 
5558.12 
(+ 669.57) 
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Figure 1
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